SCHEMBL3858554

SCHEMBL3858554

[CH2]CCCCCCC#CCCC

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 5/20 0.40
HMGCR P04035 3/20 0.40
RAB9A P51151 1/20 0.39
RECQL P46063 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
ALOX12 P18054 1/20 0.33
BLM P54132 1/20 0.33
KMT2A Q03164 1/20 0.33
MCL1 Q07820 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
EPHX2 P34913 3/20 0.32
KCNH2 Q12809 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3858349 1.00 PTPN7 (0.40) PTPN7HMGCRRAB9ARECQLTDP1
SCHEMBL8668772 1.00 PTPN7 (0.40) PTPN7HMGCRRAB9ARECQLTDP1
SCHEMBL3861203 1.00 PTPN7 (0.40) PTPN7HMGCRRAB9ARECQLTDP1
SCHEMBL7994741 1.00 PTPN7 (0.40) PTPN7HMGCRRAB9ARECQLTDP1
SCHEMBL3206990 1.00 PTPN7 (0.40) PTPN7HMGCRRAB9ARECQLTDP1
SCHEMBL1116731 0.97 PTPN7 (0.37) PTPN7HMGCRRAB9ARECQLTDP1
SCHEMBL16416623 0.93 RECQL (0.46) PTPN7HMGCRRAB9ARECQLTDP1
SCHEMBL9681594 0.90 PTPN7 (0.50) PTPN7HMGCRRAB9ARECQLTDP1
SCHEMBL61256 0.90 PTPN7 (0.50) PTPN7HMGCRRAB9ARECQLTDP1
SCHEMBL8669383 0.90 PTPN7 (0.50) PTPN7HMGCRRAB9ARECQLTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024117128-A1 INTRAOCULAR PRESSURE LOWERING AGENT, AND AGENT FOR TREATING OR PREVENTING GLAUCOMA OR OCULAR HYPERTENSION SANSHO株式会社 2024-06-06 WO disclosed
US-20240115586-A1 THERAPEUTIC AGENT FOR PULMONARY FIBROSIS SANSHO CO. LTD. (JP) 2024-04-11 US disclosed
EP-4252756-A1 THERAPEUTIC AGENT FOR PULMONARY FIBROSIS Sansho Co., Ltd. (JP) 2023-10-04 EP disclosed
US-20230108750-A1 CARBALYSOPHOSPHATIDIC ACID OCHANOMIZU UNIVERSITY (JP) 2023-04-06 US disclosed
US-10413559-B2 Method for treating demyelinating disease OCHANOMIZU UNIVERSITY (JP) 2019-09-17 US disclosed
EP-2949329-B1 THERAPEUTIC AGENT FOR DEMYELINATING DISEASE UNIV OCHANOMIZU (JP) 2019-05-01 EP disclosed
EP-2803359-B1 THERAPEUTIC AGENT FOR JOINT DISEASES SANSHO CO (JP) 2017-04-19 EP disclosed
US-20150352132-A1 THERAPEUTIC AGENT FOR DEMYELINATING DISEASE OCHANOMIZU UNIVERSITY (JP) 2015-12-10 US disclosed
EP-1756271-B1 METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM 2,2-DISUBSTITUTED EPOXIDES CSIR (ZA) 2015-12-09 EP disclosed
EP-2949329-A1 THERAPEUTIC AGENT FOR DEMYELINATING DISEASE Ochanomizu University (JP) 2015-12-02 EP disclosed
EP-1391204-A1 NERVE CELL SURVIVAL PROMOTERS CONTAINING CYCLIC PHOSPHATIDIC ACID DERIVATIVE Gencom Corporation (JP) 2004-02-25 EP disclosed
EP-1386612-A1 DRUGS FO RPROMOTING THE PROLIFERATION, DIFFERENTIATION AND/OR SURVIVAL OF GLIAL CELLS CONTAINING CYCLIC PHOSPHATIDIC ACID Gencom Corporation (JP) 2004-02-04 EP disclosed
EP-1239887-A1 COBALAMIN CONJUGATES USEFUL AS IMAGING AND THERAPEUTIC AGENTS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2002-09-18 EP disclosed
EP-1171162-A2 COBALAMIN CONJUGATES USEFUL AS ANTITUMOR AGENTS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2002-01-16 EP disclosed
US-6284784-B1 2-HYDROXYMETHYL DERIVATIVES GEORGETOWN UNIVERSITY 2001-09-04 US disclosed
WO-2001028595-A1 COBALAMIN CONJUGATES USEFUL AS IMAGING AND THERAPEUTIC AGENTS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2001-04-26 WO disclosed
WO-2000062808-A2 COBALAMIN CONJUGATES USEFUL AS ANTITUMOR AGENTS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2000-10-26 WO disclosed
EP-1015427-A1 SUBSTITUTED 2-PYRROLIDINONE ACTIVATORS OF PKC GEORGETOWN UNIVERSITY (US) 2000-07-05 EP disclosed
US-5962504-A ACTIVATOR OF PROTEIN KINASE; ANTICANCER AGENT GEORGETOWN UNIVERSITY (US) 1999-10-05 US disclosed
WO-1999012901-A1 SUBSTITUTED 2-PYRROLIDINONE ACTIVATORS OF PKC GEORGETOWN UNIVERSITY (US) 1999-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230108750-A1 CARBALYSOPHOSPHATIDIC ACID PHOSPHO1, SGMS1, PLD1 PTPN7 2293/4885HMGCR 1411/4885RAB9A 850/4885
US-20150352132-A1 THERAPEUTIC AGENT FOR DEMYELINATING DISEASE PMP22, MAG, SGMS1 PTPN7 1215/4885HMGCR 2093/4885RAB9A 2202/4885
US-10413559-B2 Method for treating demyelinating disease PMP22, MAG, SGMS1 PTPN7 1364/4885HMGCR 685/4885RAB9A 2490/4885
US-20240115586-A1 THERAPEUTIC AGENT FOR PULMONARY FIBROSIS CCL11, ELANE, MMP1 PTPN7 3368/4885HMGCR 1408/4885RAB9A 3329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.